Zenas BioPharma (ZBIO) Preferred Stock Liabilities (2023 - 2024)

Zenas BioPharma's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $55.8 million for Q2 2024.

• In Q2 2024, Preferred Stock Liabilities changed N/A year-over-year to $55.8 million; the TTM figure through Jun 2024 stood at $55.8 million (changed N/A YoY), while the FY2023 annual figure was $250.1 million, changed N/A from the prior year.
• Preferred Stock Liabilities was $55.8 million for Q2 2024 at Zenas BioPharma, roughly flat from $55.8 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $250.1 million in Q4 2023 to a low of $55.8 million in Q3 2023.